Featured Publications
Cumulative live birth rates with autologous oocytes plateau with fewer number of cycles for each year of age > 42
Seifer D, Wang S, Frankfurter D. Cumulative live birth rates with autologous oocytes plateau with fewer number of cycles for each year of age > 42. Reproductive Biology And Endocrinology 2023, 21: 94. PMID: 37872609, PMCID: PMC10591412, DOI: 10.1186/s12958-023-01144-z.Peer-Reviewed Original ResearchConceptsCumulative live birth rateLive birth rateART cyclesBirth rateDesignRetrospective cohort studyPrior ART cyclesUse of ICSIEtiology of infertilityNumber of oocytesAge categoriesSART CORS databaseYears of ageTreatment cycle numberRace/ethnicityAutologous cyclesResultsBetween 2014Ovarian reserveCohort studyBlastocyst transferWomen 46Women 42Age 45Live birthsMAIN OUTCOMEPhysician expectationsWomen with PCOS who undergo IVF: a comprehensive review of therapeutic strategies for successful outcomes
Kotlyar A, Seifer D. Women with PCOS who undergo IVF: a comprehensive review of therapeutic strategies for successful outcomes. Reproductive Biology And Endocrinology 2023, 21: 70. PMID: 37528417, PMCID: PMC10391774, DOI: 10.1186/s12958-023-01120-7.Peer-Reviewed Original ResearchConceptsPolycystic ovarian syndromeOvarian hyperstimulation syndromeOvarian stimulationStimulation protocolFrozen embryo transfer cyclesVitamin D repletionGnRH agonist triggerVitamin D levelsEmbryo transfer cyclesOvarian stimulation protocolsAntagonist cyclesHyperstimulation syndromeHypertensive disordersIVF cyclesPCOS patientsAgonist triggerOvarian syndromeOocyte yieldD levelsImproved outcomesPregnancy rateCommon causeIVF performanceTherapeutic courseInfertile couples
2023
AMH predicts miscarriage in non-PCOS but not in PCOS related infertility ART cycles
Arkfeld C, Han E, Tal R, Seifer D. AMH predicts miscarriage in non-PCOS but not in PCOS related infertility ART cycles. Reproductive Biology And Endocrinology 2023, 21: 35. PMID: 37020210, PMCID: PMC10074664, DOI: 10.1186/s12958-023-01087-5.Peer-Reviewed Original ResearchMeSH KeywordsAbortion, SpontaneousFemaleFertilization in VitroHumansInfertilityPregnancyPregnancy RateRetrospective StudiesConceptsBody mass indexMiscarriage rateMean AMHART cyclesNumber of embryosElevated AMHAMH valuesOdds ratioNon-PCOS patientsOverall miscarriage rateConfidence intervalsAutologous embryo transferSART CORS databaseMultivariate regression analysisHeterotopic pregnancyClinical pregnancyAMH levelsIVF cyclesPCOS patientsPCOS populationIndependent predictorsMass indexPatient populationOocyte bankingAutologous transfer
2020
Status of racial disparities between black and white women undergoing assisted reproductive technology in the US
Seifer D, Simsek B, Wantman E, Kotlyar A. Status of racial disparities between black and white women undergoing assisted reproductive technology in the US. Reproductive Biology And Endocrinology 2020, 18: 113. PMID: 33213467, PMCID: PMC7677830, DOI: 10.1186/s12958-020-00662-4.Peer-Reviewed Original ResearchConceptsCumulative live birth rateLive birth rateReproductive technology outcomesWhite non-Hispanic womenBody mass indexEtiology of infertilityNon-Hispanic womenMass indexBirth rateBlack womenWhite non-Hispanic patientsTechnology outcomesLogistic regressionWhite womenRetrospective cohort studyNon-Hispanic patientsIndependent prognostic factorIntra-cytoplasmic sperm injectionProportion of cyclesMultivariate logistic regressionMultiple logistic regressionReproductive technologiesNumber of embryosCycle cancellationOvarian reserveDo state insurance mandates alter ICSI utilization?
Zagadailov P, Seifer DB, Shan H, Zarek SM, Hsu AL. Do state insurance mandates alter ICSI utilization? Reproductive Biology And Endocrinology 2020, 18: 33. PMID: 32334609, PMCID: PMC7183130, DOI: 10.1186/s12958-020-00589-w.Peer-Reviewed Original ResearchConceptsIntracytoplasmic sperm injectionElective single embryo transferClinical pregnancyICSI usePreimplantation genetic testingESET rateState insurance mandatesTwin rateInsurance mandatesRetrospective cohort studyLive birth rateLower clinical pregnancyMale factor infertilitySingle embryo transferBirth rateTwin birth rateT-testICSI rateLower LBRStrength of associationCohort studyFactor infertilityART cyclesResultsFrom 2000ART coverageHigh serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology
Tal R, Seifer CM, Khanimov M, Seifer DB, Tal O. High serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology. Reproductive Biology And Endocrinology 2020, 18: 20. PMID: 32156287, PMCID: PMC7065318, DOI: 10.1186/s12958-020-00581-4.Peer-Reviewed Original ResearchConceptsLive birth rateLower live birth ratesHigh AMH groupAMH groupPCOS womenHigh AMHAMH concentrationsFirst fresh IVF/ICSI cycleBirth rateFresh IVF/ICSI cyclesGreater clinical pregnancy ratesSerum antimullerian hormone (AMH) levelsIVF/ICSI cyclesAntimullerian hormone levelsClinical pregnancy rateControlled ovarian stimulationRetrospective cohort studySerum AMH levelsPolycystic ovarian syndromeSerum AMH concentrationsLive birth outcomesNumber of embryosAMH levelsGonadotropin doseOvarian stimulation
2018
Temporal Differences in Utilization of Intracytoplasmic Sperm Injection Among U.S. Regions
Zagadailov P, Hsu A, Stern JE, Seifer DB. Temporal Differences in Utilization of Intracytoplasmic Sperm Injection Among U.S. Regions. Obstetrics And Gynecology 2018, 132: 310-320. PMID: 29995722, DOI: 10.1097/aog.0000000000002730.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsCohort StudiesFemaleFertilization in VitroHumansInfertility, FemaleInfertility, MaleLive BirthMalePregnancyPregnancy RateRetrospective StudiesSperm Injections, IntracytoplasmicTreatment OutcomeUnited StatesUnited States Dept. of Health and Human ServicesYoung AdultConceptsLive birth rateUse of ICSIICSI rateICSI utilizationBirth rateRetrospective cohort studyMale factor infertilityHuman Services (HHS) regionsIntracytoplasmic sperm injectionYears of agePreimplantation genetic testingMale factor diagnosisDepartment of HealthNondonor cyclesCohort studyFertilization cyclesFactor infertilityMale factorSperm injectionMedical indicationsMagnitude of increaseClinicGenetic testingDisease controlICSIAntimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012–2013
Tal R, Seifer DB, Wantman E, Baker V, Tal O. Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012–2013. Fertility And Sterility 2018, 109: 258-265. PMID: 29331235, DOI: 10.1016/j.fertnstert.2017.10.021.Peer-Reviewed Original ResearchAdultAnti-Mullerian HormoneArea Under CurveBiomarkersChi-Square DistributionCryopreservationDatabases, FactualEmbryo TransferFemaleFertilization in VitroHumansInfertilityLive BirthLogistic ModelsMaleOdds RatioPregnancyPregnancy RateRetrospective StudiesRisk FactorsROC CurveSingle Embryo TransferTime FactorsTreatment Outcome
2017
Differences in utilization of Intracytoplasmic sperm injection (ICSI) within human services (HHS) regions and metropolitan megaregions in the U.S.
Zagadailov P, Hsu A, Seifer DB, Stern JE. Differences in utilization of Intracytoplasmic sperm injection (ICSI) within human services (HHS) regions and metropolitan megaregions in the U.S. Reproductive Biology And Endocrinology 2017, 15: 45. PMID: 28606175, PMCID: PMC5469007, DOI: 10.1186/s12958-017-0263-4.Peer-Reviewed Original ResearchConceptsLive birth rateIntracytoplasmic sperm injectionHuman Services (HHS) regionsBirth rateUse of ICSIHigher live birth rateNon-donor cyclesUS practice patternsMale factor infertilityHigh rateDepartment of HealthFactor infertilityMale factorPractice patternsInfertility rateClinic groupSperm injectionHuman service groupsDisease controlWomenClinicInfertilityLower ratesService regionArt differs
2016
Biosimilar FSH preparations- are they identical twins or just siblings?
Orvieto R, Seifer DB. Biosimilar FSH preparations- are they identical twins or just siblings? Reproductive Biology And Endocrinology 2016, 14: 32. PMID: 27301324, PMCID: PMC4908720, DOI: 10.1186/s12958-016-0167-8.Peer-Reviewed Original ResearchConceptsFSH preparationsPregnancy rateClinical practicePhase 3 clinical trialsIncidence of OHSSOngoing pregnancy ratePolycystic ovary syndromeAdditional patient populationsPopulation of womenDose-response curveRecombinant FSH preparationsBiosimilar productsNormal respondersIVF failurePoor respondersOvary syndromeClinical efficacyPatient populationClinical trialsBiosimilar agentsSteelman-PohleyClinical useFurther comparative studiesPatientsIdentical twins
2015
Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone: a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012–2013
Seifer DB, Tal O, Wantman E, Edul P, Baker VL. Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone: a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012–2013. Fertility And Sterility 2015, 105: 385-393.e3. PMID: 26515380, DOI: 10.1016/j.fertnstert.2015.10.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersCryopreservationDatabases, FactualEmbryo TransferFemaleFertilityFertilization in VitroHumansInfertilityLinear ModelsLive BirthLogistic ModelsMiddle AgedMultivariate AnalysisOocyte RetrievalPatient SelectionPregnancyPregnancy RatePregnancy, MultipleReproductive Techniques, AssistedRetrospective StudiesRisk AssessmentRisk FactorsTreatment OutcomeYoung AdultConceptsLive birth rateAntimüllerian hormoneCancellation rateAMH levelsAssisted Reproductive Technology Clinic Outcome Reporting System databaseAssisted reproduction technology (ART) outcomesEmbryo cryopreservation ratesSerum antimüllerian hormoneTotal cancellation rateMultiple birth ratesReporting System databaseCycle startAutologous cyclesClinical pregnancyCycle cancellationPrognostic factorsAMH valuesFresh cyclesCycle outcomePrognostic indicatorAMH concentrationsRetrospective analysisMAIN OUTCOMEEmbryo transferMultivariate analysis
2014
Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis
Tal R, Tal O, Seifer BJ, Seifer DB. Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertility And Sterility 2014, 103: 119-130.e3. PMID: 25450298, DOI: 10.1016/j.fertnstert.2014.09.041.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEmbryo ImplantationFemaleFertilization in VitroHumansInfertility, FemaleMiddle AgedObservational Studies as TopicOvarian ReserveOvaryOvulation InductionPregnancyPregnancy OutcomePregnancy RatePrevalenceReproducibility of ResultsRisk FactorsSensitivity and SpecificityYoung AdultConceptsPredictor of implantationClinical pregnancy rateAntimüllerian hormoneClinical pregnancyOvarian reservePregnancy rateOdds ratioIVF/intracytoplasmic sperm injectionSystematic reviewSerum AMH levelsPolycystic ovary syndromeReproductive technologiesIntracytoplasmic sperm injectionNondonor cyclesAMH levelsOvary syndromeImplantation rateDiagnostic odds ratioObservational studyMAIN OUTCOMEClinical utilitySperm injectionPregnancyAssisted conceptionFertility treatmentFollicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation
Tal R, Seifer DB, Grazi RV, Malter HE. Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation. Reproductive Biology And Endocrinology 2014, 12: 82. PMID: 25141961, PMCID: PMC4150963, DOI: 10.1186/1477-7827-12-82.Peer-Reviewed Original ResearchMeSH KeywordsAdultCohort StudiesDown-RegulationFamily CharacteristicsFemaleFertilization in VitroFollicular FluidHumansInfertility, FemaleInfertility, MaleMaleNew York CityOocyte RetrievalOvarian ReserveOvulation InductionPlacenta Growth FactorPolycystic Ovary SyndromePregnancyPregnancy ProteinsPregnancy RateProspective StudiesUp-RegulationVascular Endothelial Growth Factor Receptor-1ConceptsNon-PCOS controlsPCOS womenOvarian stimulationSFlt-1 levelsAnti-Mullerian hormonePlacental growth factorVascular endothelial growth factorFollicular fluidOvarian syndromeSFlt-1Growth factorSoluble receptor sFlt-1BackgroundPolycystic ovarian syndromeControlled ovarian stimulationPlGF/sFltDay of hCGProspective cohort studyPolycystic ovarian syndromeNumber of oocytesEndothelial growth factorVEGF family membersCohort studyOocyte retrievalPlGF levelsVascular changesAssisted hatching and intracytoplasmic sperm injection are not associated with improved outcomes in assisted reproduction cycles for diminished ovarian reserve: an analysis of cycles in the United States from 2004 to 2011
Butts SF, Owen C, Mainigi M, Senapati S, Seifer DB, Dokras A. Assisted hatching and intracytoplasmic sperm injection are not associated with improved outcomes in assisted reproduction cycles for diminished ovarian reserve: an analysis of cycles in the United States from 2004 to 2011. Fertility And Sterility 2014, 102: 1041-1047.e1. PMID: 25086790, PMCID: PMC4184996, DOI: 10.1016/j.fertnstert.2014.06.043.Peer-Reviewed Original ResearchMeSH KeywordsChi-Square DistributionEmbryo Culture TechniquesEmbryo TransferFemaleHumansInfertility, FemaleLive BirthLogistic ModelsOdds RatioOvarian ReservePregnancyPregnancy RatePrimary Ovarian InsufficiencyRegistriesRetrospective StudiesRisk FactorsSperm Injections, IntracytoplasmicTime FactorsTreatment OutcomeUnited StatesConceptsDiminished ovarian reserveIntracytoplasmic sperm injectionElevated FSHLive birthsOvarian reserveART cyclesSperm injectionAssisted Reproductive Technology Clinic Outcome Reporting System databaseClinical pregnancy rateRetrospective cohort studyLive birth rateReproductive technology outcomesAssisted reproduction cyclesCombination of ICSIReporting System databaseCohort studyPrimary diagnosisImproved outcomesPregnancy rateMAIN OUTCOMELower oddsDiminished oddsFSHOnly indicationTechnology outcomesCharacterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes
Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. American Journal Of Obstetrics And Gynecology 2014, 211: 59.e1-59.e8. PMID: 24593938, DOI: 10.1016/j.ajog.2014.02.026.Peer-Reviewed Original ResearchConceptsSerum antimüllerian hormone levelsAntimüllerian hormone levelsClinical pregnancy ratePopulation of womenAMH levelsPregnancy rateHormone levelsHigher clinical pregnancy rateElevated AMH levelsPresence of amenorrheaMultiple pregnancy rateOvarian hyperstimulation syndromeRetrospective cohort studyHigher AMH levelsPolycystic ovarian morphologyPolycystic ovarian syndromeSyndrome phenotypeReproductive technology outcomesHyperstimulation syndromePCOS severityClinical pregnancyOvarian stimulationTotal testosteroneCohort studyOvarian syndrome
2012
Diagnosis and treatment of diminished ovarian reserve in assisted reproductive technology cycles of women up to age 40 years: the role of insurance mandates
Butts SF, Ratcliffe S, Dokras A, Seifer DB. Diagnosis and treatment of diminished ovarian reserve in assisted reproductive technology cycles of women up to age 40 years: the role of insurance mandates. Fertility And Sterility 2012, 99: 382-388.e7. PMID: 23102859, PMCID: PMC3561490, DOI: 10.1016/j.fertnstert.2012.09.026.Peer-Reviewed Original ResearchConceptsLive birth rateAge 40 yearsART cyclesART coverageElevated FSHOvarian reserveTreatment outcomesReproductive technology treatment outcomesSpecific infertility diagnosisState insurance coverageReproductive technology cyclesDiminished ovarian reserveProportion of cyclesCross-sectional studyBirth rateReporting System databaseInsurance mandatesMix of patientsProvider factorsInfertility diagnosisMAIN OUTCOMEFSHSignificant associationTreatment prognosisAdditional studies
2011
Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels
Buyuk E, Seifer DB, Younger J, Grazi RV, Lieman H. Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels. Fertility And Sterility 2011, 95: 2369-2372. PMID: 21497340, DOI: 10.1016/j.fertnstert.2011.03.071.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersChi-Square DistributionEmbryo TransferFemaleFertilization in VitroFollicle Stimulating Hormone, HumanFollicular PhaseHumansInfertility, FemaleNew YorkOocyte RetrievalOvulationOvulation InductionPregnancyPregnancy RateRetrospective StudiesTime FactorsTreatment OutcomeUp-RegulationConceptsAnti-Müllerian hormoneNumber of oocytesClinical pregnancy rateSerum AMH levelsDiminished ovarian reserveAMH levelsFSH levelsDay 3 embryosElevated FSHOvarian responseART cyclesPregnancy rateEarly follicular FSH levelsFollicle-stimulating hormone levelsSerum anti-Müllerian hormoneCycle cancellation rateSerum FSH levelsReproductive technology programCycle cancellationOvarian reserveRetrospective studyHormone levelsMAIN OUTCOMECancellation rateRandom sera
2007
Social concerns of women undergoing infertility treatment
Finamore PS, Seifer DB, Ananth CV, Leiblum SR. Social concerns of women undergoing infertility treatment. Fertility And Sterility 2007, 88: 817-821. PMID: 17418158, DOI: 10.1016/j.fertnstert.2007.01.009.Peer-Reviewed Original ResearchConceptsInfertility treatment centersFrequent doctor visitsCaribbean-American womenCross-sectional questionnaireRace/ethnicityInfertility specialistsInfertility statusInfertility treatmentDoctor visitsMAIN OUTCOMENumber of visitsHigh school educationMost womenTreatment centersDemographic dataInfertilityWomenDemographic characteristicsSuccess rateAmerican womenCertain womenVisitsLevel of educationQuestionnaireAssociation
2004
Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol
Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertility And Sterility 2004, 82: 1323-1329. PMID: 15533354, DOI: 10.1016/j.fertnstert.2004.03.061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEstradiolFemaleFertilization in VitroFollicle Stimulating HormoneGlycoproteinsHumansInhibinsMultivariate AnalysisOsmolar ConcentrationOvulation InductionPredictive Value of TestsPregnancyPregnancy RateRetrospective StudiesTesticular HormonesTime FactorsTreatment OutcomeConceptsReproductive technology outcomesMullerian-inhibiting substanceYears of ageMultivariate regression analysisInhibin BPregnancy outcomesIVF outcomesAntimullerian hormoneHigher clinical pregnancy rateSerum samplesAvailable serum markersDay 3 FSHSerum antimullerian hormoneClinical pregnancy rateClinical pregnancy outcomesInhibin B levelsFollicle-stimulating hormoneConsecutive serum samplesMüllerian-inhibiting substanceGreater prognostic valueTechnology outcomesRegression analysisClinical pregnancyOvarian stimulationOvulation induction
1998
Elevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential
Friedman C, Seifer D, Kennard E, Arbogast L, Alak B, Danforth D. Elevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential. Fertility And Sterility 1998, 70: 836-839. PMID: 9806563, DOI: 10.1016/s0015-0282(98)00301-x.Peer-Reviewed Original ResearchConceptsFF VEGF concentrationsAmpules of gonadotropinsVEGF concentrationsClinical pregnancyChart reviewFollicular fluid vascular endothelial growth factorFollicular fluid vascular endothelial growth factor concentrationsDay 3 FSH levelsFollicular fluid VEGF concentrationsVascular endothelial growth factor concentrationsClinical pregnancy rateEstradiol serum concentrationsPeak estradiol levelsRetrospective chart reviewUniversity teaching centerVascular endothelial growth factorNumber of oocytesYears of ageEndothelial growth factorGrowth factor concentrationsFF VEGFSingle IVFFSH levelsPatient ageEstradiol levels